ES 
EN 
NephCure, a leading nonprofit organization dedicated to improving the lives of people affected by rare kidney diseases, is proud to recognize the inaugural C3G Awareness Day on September 25, 2025. This day is dedicated to raising awareness and understanding of C3 glomerulopathy (C3G), an ultra-rare kidney disease that can progress to kidney failure.
C3G Awareness Day aims to elevate patient and caregiver voices, provide education about this complex disease, and bring together the broader rare kidney community.
C3G is caused by abnormal activity in the complement system, a part of the immune system that helps the body fight infections. When the complement system is overactive, it can attack the kidneys, leading to inflammation, scarring, and progressive kidney damage. C3G affects people of all ages, but because it is so rare and difficult to diagnose, many patients spend years searching for answers before finding the right care.
This year, the C3G community has seen important progress with the approval of two FDA-approved Opciones de tratamiento; FABHALTA y EMPAVELI. While more work remains to improve access and develop additional therapies, these milestones bring new hope to those impacted by C3G.
NephCure has launched a dedicated C3G Awareness Day webpage featuring educational resources, patient stories, and tools to help spread awareness. There, users can also find a downloadable social media toolkit, which includes ready-to-use graphics and captions. The toolkit allows patients, caregivers, friends, and supporters to share stories and messages of solidarity, whether they are directly affected by C3G or another rare kidney disease.
We thank our partners Apellis, Novartis, Sobi, CompCure, and C3G Warriors, for their commitment to improving the lives of C3G patients and families.
To learn more about C3G Awareness Day, read patient stories, or download the toolkit, visit NephCure.org/c3g-awareness-day-2025.
Acerca de NephCure:
NephCure’s mission is to empower people with rare, protein-spilling kidney diseases to take charge of their health while leading the revolution in research, new treatments, and care. Since 2000, NephCure has invested more than $40 million in kidney disease research and helped transform the treatment landscape through advocacy, education, and support. NephCure is a U.S. tax-exempt 501(c)(3) public charity.
